Vertero Therapeutics Launches Phase 1 Trial of VT-5006, First-in-Class Gut-Selective Therapy for Parkinson's Disease
核心洞察
Vertero Therapeutics (搜索) has initiated a Phase 1 clinical trial of VT-5006 (搜索), a first-in-class, gut-selective small molecule targeting CsgA (搜索) to treat Parkinson's disease.
The novel oral therapeutic aims to reduce alpha-synuclein (搜索) aggregation and inflammation by targeting microbial amyloid in the gastrointestinal wall that propagates to the brain.
Preclinical studies demonstrated reduced brain pathology and inflammation, improved motor function, and slowed disease progression with a strong safety profile.
Vertero Therapeutics (搜索) announced the initiation of a Phase 1 clinical trial for VT-5006 (搜索), a first-in-class, gut-selective small molecule designed to treat Parkinson's disease by targeting peripheral triggers that drive neurodegeneration. The novel approach represents a significant departure from current therapies that primarily focus on symptom management.
Novel Mechanism Targets Gut-Brain Connection
VT-5006 (搜索) acts on CsgA (搜索), a microbial amyloid present in the gastrointestinal wall that drives aggregation of alpha-synuclein (搜索) (αSyn) and inflammation. This peripheral target propagates to the brain and provokes Parkinson's disease progression. By targeting CsgA, VT-5006 aims to reduce the load of aggregation and dampen inflammation, potentially both alleviating symptoms and slowing disease progression to preserve functionality for affected individuals.
"This program reflects our strategy to change the way we approach neurodegenerative diseases by targeting causative triggers in peripheral systems that fuel these diseases," said Becca Senter, Ph.D., Chief Scientific Officer at Vertero. "We believe VT-5006 (搜索) could effectively intervene upstream in the peripheral system to delay onset, slow progression and preserve quality of life for people with Parkinson's disease."
Two-Phase Clinical Trial Design
The Phase 1a portion of the study is enrolling healthy volunteers to receive VT-5006 (搜索) either as a single dose or once daily for seven days. Primary endpoints include safety, tolerability and pharmacokinetics of VT-5006 at sequentially-ascending doses compared to placebo.
The Phase 1b portion will include adults who have been diagnosed with Parkinson's disease in the last 10 years, who are at early or moderate stage of disease (Hoehn and Yahr scale < 3), and who are CsgA (搜索)-positive. This patient selection criteria ensures enrollment of individuals who may benefit most from the targeted mechanism of action.
Promising Preclinical Foundation
The clinical trial is informed by promising preclinical studies which demonstrated reduced pathology and inflammation in the brain, improved motor function, and slowed disease progression, with a strong safety profile. These findings support the therapeutic potential of targeting peripheral triggers in neurodegenerative disease treatment.
Philip Kremer, MD, PhD, Research Director Neurology at Centre for Human Drug Research (CHDR) and principal investigator for the study, emphasized the unmet medical need: "Parkinson's carries a considerable burden, not only for the affected individual but for caregivers and loved ones. Current therapies are limited primarily to symptom management, so there remains a persistent and urgent need for novel approaches to meaningfully address the disease and slow progression."
Peripheral-Focused Therapeutic Strategy
Vertero Therapeutics (搜索) positions itself as a clinical-stage company pioneering science beyond the brain to treat neurodegenerative diseases at their source. The company's development pipeline of differentiated therapies targets the peripheral nervous system to delay onset and slow progression of challenging conditions such as Parkinson's disease.
Dr. Kremer noted the evolving understanding of disease mechanisms: "As the healthcare community comes to understand the causative connection between peripheral triggers and neurodegenerative diseases, the insights from this trial will help further refine a strong clinical development program to demonstrate how this selective small molecule can alter the trajectory of Parkinson's disease."
The company also has an asset targeting bile acid dysregulation in early development for undisclosed indications, suggesting a broader pipeline focused on peripheral mechanisms in neurodegeneration.